Immunotherapy for lung cancer in high-altitude areas
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well immunotherapy works and what side effects it may cause in people with non-small cell lung cancer who live in high-altitude areas (Qinghai or Shaanxi). It tests whether altitude affects treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a clear diagnosis of non-small cell lung cancer (like adenocarcinoma, squamous cell, or large cell).
- You must be receiving immunotherapy for lung cancer for the first time.
- You must have had at least 2 rounds of immunotherapy and a check-up to see if it's working.
- You must be 18 years or older.
- You must have lived in Qinghai or Shaanxi province since birth (not moved there from another altitude).
- You cannot have moved between different altitudes (like from Qinghai to Shaanxi) or have parents who moved from another area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic information from tumor tissue of people with non-small cell lung cancer who had immunotherapy before surgery but still had some cancer cells left. The goal is to understand why the cancer did not completely respond to treatment.
This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy and a type of high-dose radiation therapy called Quad Shot for people with advanced lung cancer that has no known gene mutations. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
Hear when a new Non-small Cell Lung Cancer(NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.